Neurotrophins Market Analysis

  • Report ID: 5404
  • Published Date: Nov 26, 2025
  • Report Format: PDF, PPT

Neurotrophins Market Segmentation:

Type Segment Analysis

The brain-derived neurotrophic factor segment in the neurotrophins market is estimated to gain the largest revenue share of 60% in the year 2035. The soaring prevalence of neurological disorders is a primary growth driver for the BDNF segment. These conditions often involve reduced BDNF levels, contributing to neuronal degeneration. The World Health Organization (WHO) reports a 25% increase in the prevalence of neurological disorders globally, including conditions like Alzheimer's and Parkinson's. The BDNF segment in the market is experiencing significant growth, propelled by increasing neurological disorder prevalence, advancements in BDNF-based therapies, government research investments, regulatory support, patient advocacy efforts, and international collaboration. As these growth drivers continue to shape the landscape, the BDNF segment is poised for transformative progress in the realm of neurological disorder management.

End User Segment Analysis

The hospitals segment in the neurotrophins market is expected to garner a significant share in the year 2035. Hospitals play a pivotal role in the market, serving as primary institutions for diagnosis, treatment, and care of patients with neurological disorders. The growth of this segment is influenced by several key drivers, each of which contributes to the development of advanced therapies and improved patient care. The relationship between hospitals and regulatory authorities is a significant growth driver for the hospitals segment. Regulatory support, including swift approvals for new neurotrophin-based therapies, is essential for facilitating pharmaceutical innovation. Recent approvals indicate a conducive regulatory environment that encourages hospitals and pharmaceutical companies to develop and introduce innovative treatments. These approvals are a testament to the commitment of regulatory agencies to effectively address neurological disorders and enhance patient care.

Hospitals are increasingly adopting a patient-centric approach to neurological care. This approach emphasizes not only diagnosis and treatment but also patient education, support, and empowerment. Patients with neurological disorders often require long-term care and support, and hospitals are recognizing the importance of addressing these needs.

Our in-depth analysis of the global market includes the following segments:

           Type

  • Nerve Growth Factor
  • Brain-Derived Neurotrophic Factor

 

   

           End User

  • Hospitals
  • Pharmaceutical
  • Research Institutions

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of neurotrophins is evaluated at USD 8.28 billion.

The global neurotrophins market size was worth over USD 7.77 billion in 2025 and is poised to grow at a CAGR of around 7.3%, reaching USD 15.72 billion revenue by 2035.

Asia Pacific neurotrophins market is projected to secure the largest share of 40%, driven by expanding international research collaborations and the growing role of patient advocacy groups supporting patient-centric neurological care.

Key players in the market include Genentech, Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., Amgen Inc., Eli Lilly and Company, Novartis International AG.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos